Searchable abstracts of presentations at key conferences in endocrinology

ea0063p299 | Reproductive Endocrinology 1 | ECE2019

High prevalence of psychopathologies among transgender patients presenting at a large tertiary center: implication for the treating clinicians

Kerem Gil , Greenman Yona , Yaish Iris , Sofer Yael , Stern Naftali , Tordjman Karen

Background and aim of study: Endocrinologists play a central role in the gender affirming process that transgender people chose to undergo, and may be ill-prepared to recognize and manage psychologic difficulties that accompany gender dysphoria. We sought to characterize the patient population currently under our care with respect to their mental health, and to address the question of possible differences between transwomen (TW) and transmen (TM).Methods...

ea0099ep396 | Reproductive and Developmental Endocrinology | ECE2024

Low dose estradiol gender-affirming hormone therapy (GAHT) generates rapid feminizing body changes in transgender women: a dual energy x-ray absorptiometry-based prospective study

Yaish Iris , Gindis Guy , Buch Asaf , Sofer Yael , Greenman Yona , Arbiv Mira , Moshe Yaffa , Tordjman Karen

Background and Aim: We previously demonstrated that low-dose estradiol (E2) administered sublingually alone for 6 months in treatment-naïve trans women (TW), suppressed testosterone to the same degree, but generated higher serum E2 levels as the same oral dose combined with cyproterone acetate. We now sought to assess the possible differential impact of these approaches on anthropometric and body composition measurements, sex-dependent indicators with proven metabolic pro...

ea0090p182 | Reproductive and Developmental Endocrinology | ECE2023

Sublingual estradiol only, offers no apparent advantage over combined oral estradiol and cyproterone acetate, for Gender Affirming Hormone Therapy (GAHT) of treatment-naïve transwomen: Results of a prospective pilot study

Gindis Guy , Yaish Iris , Greenman Yona , Moshe Yaffa , Arbiv Mira , Buch Asaf , Sofer Yael , Shefer Gabi , Tordjman Karen

Background: The standard approach for Gender-Affirming Hormone Therapy (GAHT) of transgender women (TW) in Israel is oral estradiol (OE) combined with the potent anti-androgen cyproterone acetate (CA). Recently, many of our non-binary patients have requested sublingual estradiol (SLE) without CA, under the unproven belief it preserves erectile function, and does not induce depression. Preliminary data in a few subjects, who self-practiced this approach, suggested it also maint...

ea0063p303 | Reproductive Endocrinology 1 | ECE2019

Evidence for preserved ovarian reserve in transgender men receiving testosterone therapy: Anti-mullerian hormone serum levels decrease modestly after one year of treatment

Yaish Iris , Malinger Gad , Azem Foad , Sofer Yael , Golani Nechama , Tordjman Karen , Amir Hadar , Stern Naftali , Greenman Yona

Background: Although successful pregnancies carried by transgender men have been reported, long-term effects of testosterone therapy on fertility remain unknown.Aims: To study markers of ovarian reserve during testosterone therapy.Methods: Prospective open-label study of transgender men prior and during treatment with testosterone. Sampling was conducted at baseline and 12 months after treatment initiation.Ma...